Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors

Clinical Cancer Research

Volumn 9, Issue 1 II, 2003, Pages

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANASTROZOLE; ANDROGEN; AROMATASE; AROMATASE INHIBITOR; CORTICOTROPIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEOXYPYRIDINOLINE; ESTROGEN; EXEMESTANE; HYDROCORTISONE; LETROZOLE; PYRIDINOLINE; TAMOXIFEN;

ACNE; ANDROGEN SYNTHESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTRICHOSIS; LIPID BLOOD LEVEL; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; STEADY STATE; WEIGHT GAIN;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; LIPIDS; NITRILES; POSTMENOPAUSE; TRIAZOLES;

EID: 0037242971     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
2. Jensen, E. V., Block, G. E., Smith, S., Kyser, K., and DeSombre, E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr., 34: 55-70, 1971.
3. Sedlacek, S. M., and Horwitz, K. B. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids, 44: 467-484, 1984.
4. Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C. P., Vogel, C. L., Eiermann, W., Wolter, J. M., Steinberg, M., Webster, A., and Lee, D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Arimidex Study Group. Cancer (Phila.), 83: 1142-1152, 1998.
5. Dombemowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., Fornasiero, A., Hoffmann, W., Michel, J., Hatschek, T., Tjabbes, T., Chaudri, H. A., Homberger, U., and Trunet, P. F. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol., 16: 453-461, 1998.
6. Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J. L., Nasurdi, C., Mennel, R. G., Cervek, J., Fowst, C., Polli, A., di Salle, E., Arkhipov, A., Piscitelli, G., Miller, L. L., and Massimini, G. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J. Clin. Oncol., 18: 1399-1411, 2000.
7. Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., Webster, A., Morris, C., Elledge, R., and Buzdar, A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol., 20: 3386-3395, 2002.
8. Howell, A., Robertson, J. F., Quaresma, A. J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., and Morris, C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol., 20: 3396-3403, 2002.
9. Harvey, H. A., Santen, R. J., Osterman, J., Samojlik, E., White, D. S., and Lipton, A. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer (Phila.), 43: 2207-2214, 1979.
10. Santen, R. J., Worgul, T. J., Samojlik, E., Interrante, A., Boucher, A. E., Lipton, A., Harvey, H. A., White, D. S., Smart, E., Cox, C., and Wells, S. A. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N. Engl. J. Med., 305: 545-551, 1981.
11. Segaloff, A., Weeth, J. B., Meyer, K. K., Rongone, E. L., and Cunningham, M. E. G. Hormonal therapy in cancer of the breast. XIX. Effect of oral administration of delta-1-testololactone on clinical course and hormonal excretion. Cancer (Phila.), 15: 633-635, 1962.
12. Van Rymenant, M., Coune, A., Tagnon, H. J., and Somon, S. Le traitement hormonal du cancer du sein en phase avancee. Methodes d'etudes: comparaison de la delta-1-testololactone avec le propionate de tetosterone. Acta Clin. Belg., 18: 469-479, 1963.
13. Buzdar, A., and Howell, A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin. Cancer Res., 7: 2620-2635, 2001.
14. Goss, P. E., and Strasser, K. Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol., 19: 881-894, 2001.
15. Plourde, P. V., Dyroff, M., Dowsett, M., Demers, L., Yates, R., and Webster, A. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J. Steroid Biochem. Mol. Biol., 53: 175-179, 1995.
16. Demers, L. M., Lipton, A., Harvey, H. A., Kambic, K. B., Grossberg, H., Brady, C., and Santen, R. J. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J. Steroid Biochem. Mol. Biol., 44: 687-691, 1993.
17. Zilembo, N., Noberasco, C., Bajetta, E., Martinetti, A., Mariani, L., and Orefici, S. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br. J. Cancer. 72: 1007-1012, 1995.
18. Bajetta, E., Zilembo, N., Dowsett, M., Guillevin, L., Di Leo, A., Celio, L., Martinetti, A., Marchiano, A., Pozzi, P., Stani, S., and Bichisao, E. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur. J. Cancer, 35: 208-213, 1999.
19. Yates. R. A., Dowsett. M., Fisher, G. V., Selen, A., and Wyld, P. J. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br. J. Cancer, 73: 543-548. 1996.
20. Spinelli, R., Jannuzzo, M. G., Poggesi, I., Frevola, L., Broutin, F., and Cicioni, P. Pharmacokinetics (PK) of Aromasin (Exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). Eur. J. Cancer, 35 (Suppl 4): S295, 1999.
21. Sioufi, A., Sandrenan, N., Godbillon, J., Trunet, P., Czendlik, C., and Howard, H. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after 2.5 mg single oral administration. Biopharm. Drug Dispos., 18: 489-497, 1997.
22. Geisler, J., King, N., Dowsett. M., Ottestad, L., Lundgren, S., Walton. P., Kormeset, P. O., and Lonning. P. E. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer, 74: 1286-1291, 1996.
23. Geisler, J., Anker, G., Dowsett, M., and Lonning, P. E. Letrozole suppresses plasma estrogen levels in postmenopausal breast cancer patients more completely than anastrozole. Proc. Am. Soc. Clin. Oncol., 19: 102a, 2000.
24. Bajetta, E., Zilembo, N., Noberasco, C., Martinetti, A., Mariani, L., Ferrari, L., Buzzoni, R., Greco, M., Bartoli, C., Spagnoli, I., Danesini, G. M., Artale, S., and Paolini, J. The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Eur. J. Cancer, 33: 587-591, 1997.
25. Geisler, J., Bernsten, L., Ottestad, B., Lindtjorn, B., Dowsett. M., and Lonning, P. E. Neoadjuvant treatment with anastrozole (Arimidex) causes profound suppression of intra-tumor estrogen levels. Proc. Am. Soc. Clin. Oncol., 18: 82a, 1999.
26. Miller, W. R. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr. Relat. Cancer, 6: 187-195, 1999.
27. Dixon, J. M., Grattage, L., Renshaw, L., and Miller, W. R. Exemestane as neoadjuvant treatment for locally advanced breast cancer: endocrinologic and clinical endpoints. Breast Cancer Res. Treat., 64: 53, 2000.
28. Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., and Brady, C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol., 19: 3357-3366, 2001.
29. Grimm, S. W., and Dyroff, M. C. Inhibition of human metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab. Dispos., 25: 598-602, 1997.
30. Wirz, B., Valles, B., Parkinson, A., Madan, A., Probst, A., and Zimmerman, A. CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole (Femara). 7th North American Meeting, 10: 359, 1996.
31. Anonymous. Exemestane for advanced breast cancer. Med. Lett. Drugs Ther., 42: 35-36, 2000.
32. Dowsett, M., Pfister, C., Johnson, S. R. D., Miles, D. W., Houston, S. J., and Verbeek, J. A. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin. Cancer Res., 5: 2338-2343, 1999.
33. The ATAC Trialists' Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the "Arimidex and Tamoxifen Alone or in Combination" (ATAC) trial. Br. J. Cancer, 85: 317-324, 2001.
34. Michaud, L. B., and Buzdar, A. U. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf., 21: 297-309, 1999.
35. Dewar, J., Nabholtz, J-M., Bonneterre, J., Buzdar, A., Robertson, J. F., and Thurlimann, B. The effect of anastrozole (Arimidex) on serum lipids: data from a randomized comparison of anastrozole (AN) versus tamoxiten (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res. Treat., 64: 51, 2000.
36. Wojtacki, J., Kruszewski, W. J., Les'niewski-Kmak, K., S'liwin'ska, M., Czyzewska. K., and Kruszewska, E. Short-term effects of anastrozole therapy on serum lipid profile in patients with breast cancer, previously treated with tamoxifen. Preliminary report. Nowotwory, 51: 43-47, 2001.
37. Elisaf, M. S., Bairaktari. E., Nicolaides, C., Kakaidi, B., Tzallas, C. S., and Katsaraki, A. Effect of letrozole on the lipid in postmenopausal women with breast cancer. Eur. J. Cancer, 37: 1510-1513, 2001.
38. Engan, T., Krane, J., Johannessen, D. C., and Kvinnsland, S. Plasma changes in breast cancer patients during endocrine therapy: lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res. Treat., 36: 287-297, 1995.
39. Lohrisch, C., Paridaens, R., Dirix, L. Y., Beex, M., Nooij, M., and Cameron, D. No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin [Exemestane (E)] in first-line treatment of metastatic breast cancer (MBC): companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacia Upjohn. Proc. Am. Soc. Clin. Oncol., 20: 43a, 2001.
40. Plourde, P. V., Dyroff, M., and Dukes, M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat., 30: 103-111, 1994.
41. Buzdar, A., and Esparza-Guerra, L. Anastrozole "Arimidex" does not impair adrenal cortisol or aldosterone synthesis in postmenopausal women with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., 20: 52b, 2001.
42. Bisagni, G., Cocconi, G., Scaglione, F., Fraschini, F., Pfister, C. H., and Trunet, P. F. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. Ann. Oncol., 7: 99-102, 1996.
43. Evans, T. R., di Salle, E., Ornati, G., Lassus, M., Benedetti, M. S., Pianezzola, E., and Coombes, R. C. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res., 52: 5933-5939, 1992.
44. Goss, P., Grynpas, M., Qi, S., and Hu, H. The effects of exemestane on bone and lipids in the ovariectomized rat. Breast Cancer Res. Treat., 69: 224, 2001.
45. Lai, J. M., Taxel. P., and Raisz, L. G. The effect of aromatase inhibition on bone turnover in older men. J. Am. Geriatr. Soc., 46: S79, 1998.
46. Harper-Wynne, C., Ross, G., Sacks, N., Gui. G., and Dowsett, M. Effects of the aromatase inhibitor letrozole in healthy postmenopausal women rationale for prevention. Proc. Am. Soc. Clin. Oncol., 20: 335b, 2001.
47. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359: 2131-2139, 2002.
48. Rose, C., Vtoraya, O., Pluzanska, A., Neave, F., Clemens, M., Chaudri-Ross, H. A., Wyld, P., and Lang, R. Letrozole (Femara) versus anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., 21: 34a, 2002.